News Bayer's Hyrnuo moves first-line for lung cancer in China Bayer's oral HER2 inhibitor Hyrnuo has been approved in China as a frontline therapy for advanced, HER2-mutant non-small cell lung cancer.
News Bayer moves Hyrnuo into frontline lung cancer treatment Bayer chases after Boehringer with an FDA approval for oral HER2 inhibitor Hyrnuo in previously untreated HER2+ lung cancer.
News Boehringer advances duo for aggressive cancers into phase 3 Boehringer Ingelheim steps up its push into oncology with phase 3 trials for pathfinder product Hernexeos and obrixtamig in hard-to-treat cancers.
Oncology ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C... At ASCO 2026, BI Global Head of Oncology Itziar Canamasas spoke with pharmaphorum about the company's ASCO data and broader oncology strategy.
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent US approval for Hernexeos in NSCLC.
News Boehringer gets FDA's second 'national priority' approval Boehringer Ingelheim's lung cancer drug Hernexeos has become the second medicine approved after an FDA national priority review.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.